ADPT
Adaptive Biotechnologies CorporationNASDAQHealthcare$14.81+2.63%ClosedMarket Cap: $2.28B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
9.85
P/S
7.83
EV/EBITDA
-63.83
DCF Value
$-26.61
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.2%
Operating Margin
-20.6%
Net Margin
-21.5%
ROE
-30.0%
ROA
-11.6%
ROIC
-13.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $71.7M | 74.6% | $-12.8M | $-13.6M | $-0.09 | — |
| FY 2025 | $277.0M | 74.2% | $-57.1M | $-59.5M | $-0.39 | — |
| Q3 2025 | $94.0M | 80.7% | $10.3M | $9.5M | $0.06 | — |
| Q2 2025 | $58.9M | 69.4% | $-25.0M | $-25.6M | $-0.17 | — |
| Q1 2025 | $52.4M | 67.6% | $-29.6M | $-29.9M | $-0.20 | — |
| Q4 2024 | $47.5M | 62.0% | $-33.8M | $-33.7M | $-0.23 | — |
| FY 2024 | $179.0M | 59.7% | $-162.5M | $-159.5M | $-1.08 | — |
| Q3 2024 | $46.4M | 64.1% | $-32.6M | $-32.1M | $-0.22 | — |
| Q2 2024 | $43.2M | 55.3% | $-47.3M | $-46.2M | $-0.31 | — |
| Q1 2024 | $41.9M | 56.9% | $-48.8M | $-47.5M | $-0.33 | — |
| Q4 2023 | $45.8M | 57.2% | $-71.1M | $-69.4M | $-0.48 | — |
| FY 2023 | $170.3M | 55.6% | $-227.0M | $-225.3M | $-1.56 | — |